Stay updated on Pediatric Emicizumab SC in Hemophilia A Clinical Trial
Sign up to get notified when there's something new on the Pediatric Emicizumab SC in Hemophilia A Clinical Trial page.

Latest updates to the Pediatric Emicizumab SC in Hemophilia A Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedAdded study locations for California, Colorado, Georgia, Illinois, Michigan, New York, Oregon, Washington, and Lombardy, and updated the page revision to v3.3.3. Removed the HHS Vulnerability Disclosure section and several regional location entries, with the revision history updated from v3.3.2 to v3.3.3.SummaryDifference0.7%

- Check23 days agoNo Change Detected
- Check44 days agoChange DetectedAdded a PubMed auto-fill note indicating publications are automatically pulled from PubMed and updated the revision from v3.2.0 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check52 days agoChange DetectedRemoval of the top government funding banner. The page now presents the study details without that notice, and the study information remains unchanged.SummaryDifference0.3%

- Check66 days agoChange DetectedNo additions or deletions detected between the two screenshots. The page still presents the HAVEN 2 study details and related information.SummaryDifference0.3%

- Check95 days agoChange DetectedCore content updated: a government funding and operating status notice has been added and the version updated to v3.2.0; the prior v3.1.0 tag was removed.SummaryDifference0.6%

- Check102 days agoChange Detected- Standardized the disease name to the proper form Hemophilia A and updated the revision to v3.1.0, replacing Hemophilia a and v3.0.2.SummaryDifference0.0%

Stay in the know with updates to Pediatric Emicizumab SC in Hemophilia A Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pediatric Emicizumab SC in Hemophilia A Clinical Trial page.